Pair Name	Oxidized tea polyphenol, Nimotuzumab
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Gene Regulation	Down-regulation	Expression	EGFR	hsa1956
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	STAT3	hsa6774
	Down-regulation	Phosphorylation	GSK3B	hsa2932
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	NCI-H1781	Minimally invasive lung adenocarcinoma	Homo sapiens (Human)	CVCL_1494
In Vivo Model	NCI-H1781 cells (5 × 106 cells per mice) were subcutaneously injected into the flank of each nu/nu mice. 3 days later, the mice were treated by intraperitoneal injection OTP-3 and nimotuzumab (three times per week) for the indicated period.
Result	OTP-3 can also serve as an effective therapeutic agent in NSCLC where it can augment the effects of nimotuzumab, a valuable property for combination agents.